Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Neurobiol Dis. 2019 Jun 15;130:104511. doi: 10.1016/j.nbd.2019.104511

Figure 4. SR-expressing reactive astrocytes in the hippocampus of AD subjects are neurotoxic.

Figure 4

Representative images showing SR (green), GFAP (magenta), and C3 (turquoise) immunostaining of control (A–D) and AD subjects (E–H). White arrows show cells that express all three markers. Scale bars = 25μm. (I) The number of GFAP+/C3+ and GFAP+/C3+/SR+ cells/mm3 was increased in AD subjects (filled circles; Braak III: gray, IV: blue; V: black, VI: orange) compared to controls (open circles) in the entire hippocampus (GFAP/C3: F2,15=16.84**, P=0.0009**; GFAP/C3/SR: F2,15=8.68**, P=0.03**). Hippocampal subfields were also analyzed separately: DG (GFAP/C3: F2,15=2.45, P=0.12; GFAP/C3/SR: F2,15=7.14**, P=0.04**), CA4 (GFAP/C3: F2,15=2.16, P=0.15; GFAP/C3/SR: F2,15=2.48, P=0.18), CA3 (GFAP/C3: F2,15=1.71, P=0.21; GFAP/C3/SR: F2,15=2.36, P=0.13), CA2 (GFAP/C3: F2,15=0.35**, P=0.58**; GFAP/C3/SR: F2,15=0.58**, P=0.48**), and CA1 (GFAP/C3: F2,15 = 5.49, P = 0.01; GFAP/C3/SR: F2,15=5.32, P=0.01). * indicates significant differences between control and AD. ** indicates values are adjusted for significant effect of exposure to AD medication. Values represent the mean ± SEM.